Genomind Genecept Assay

Genomind has launched a new, expanded version of its Genecept Assay, a pharmacogenetic test to help guide psychiatric treatment. The company has added eight more genes to its existing panel of 10, based on a meta-analysis of hundreds of published studies showing that variations in these genes can inform decisions for psychiatric treatment. The test now covers chronic pain and substance abuse, as well as depression, anxiety, obsessive-compulsive disorder, attention-deficit hyperactivity disorder, bipolar disorder, post-traumatic stress disorder, autism and schizophrenia. It also covers more than 15 drug classes, 103 FDA-approved medications, and 97 percent of drugs used to treat depression, anxiety, bipolar disorder, schizophrenia, attention-deficit disorder, autism, and pain disorders.